V2X Inc VVX 深 沪
等待开盘 01-14 09:30:00 美东时间
65.69
+0.640
+0.98%
华盛通- 最 高66.48
- 今 开65.895
- 成交量 9.22万股
- 最 低 64.6801
- 昨 收 65.05
- 总市值 20.72亿
- 52周最高 66.48
- 市盈率 静 60.54
- 换手率 0.00%
- 52周最低 41.075
- 委 比 -83.78%
- 总股本 3153.51万
- 历史最高 69.75
- 量 比 0.75
- 振 幅 2.77%
- 历史最低 12.50
- 每 手 1
- 风险率 4.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多V2X Inc. Awarded Contract Under Missile Defense Agency's $151B SHIELD Indefinite-Delivery/Indefinite-Quantity Contract Vehicle
V2X, Inc. (NYSE: VVX) is pleased to announce it has been awarded a contract under the Missile Defense Agency's (MDA) Scalable Homeland Innovative Enterprise Layered Defense (SHIELD)
01-12 20:53
Under the Radar: The Early Blueprint of a Multi-Bagger
One of the great myths of investing is that multi-baggers are discovered by fin...
2025-12-31 02:15
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
Citigroup Initiates Coverage On V2X with Neutral Rating, Announces Price Target of $62
Citigroup analyst Jason Gursky initiates coverage on V2X (NYSE:VVX) with a Neutral rating and announces Price Target of $62.
2025-12-12 23:56
V2X Awarded 10-Yr, $425M Indefinite-Delivery, Indefinite-Quantity Contract To Modernize And Upgrade Cockpit Displays For U.S. Air Force F-16 Fleet
V2X, Inc. (NYSE:VVX), announced it has been awarded a 10-year, $425 million indefinite-delivery, indefinite-quantity contract to modernize and upgrade cockpit displays for the U.S. Air Force F-16 fleet.Under the
2025-12-01 20:35
V2X Shareholder Vertex Aerospace Sells 2.25M Shares, To Repurchase 363K Shares From Offering, Ends Board Rights
V2X, Inc. (NYSE:VVX) ("V2X"), a leading provider of global mission solutions, announced today the sale of 2.25 million shares of its common stock on an underwritten basis by Vertex Aerospace Holdco LLC ("Vertex
2025-11-12 19:33
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
Stifel Maintains Buy on V2X, Raises Price Target to $65
Stifel analyst Jonathan Siegmann maintains V2X (NYSE:VVX) with a Buy and raises the price target from $63 to $65.
2025-11-04 20:36
